Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $127.6 million.

  • Cytek Biosciences' Shares Outstanding (Weighted Average) fell 268.22% to $127.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.6 million, marking a year-over-year decrease of 268.22%. This contributed to the annual value of $130.6 million for FY2024, which is 345.33% down from last year.
  • As of Q3 2025, Cytek Biosciences' Shares Outstanding (Weighted Average) stood at $127.6 million, which was down 268.22% from $127.6 million recorded in Q2 2025.
  • Cytek Biosciences' Shares Outstanding (Weighted Average)'s 5-year high stood at $136.2 million during Q3 2023, with a 5-year trough of $31.9 million in Q2 2021.
  • For the 5-year period, Cytek Biosciences' Shares Outstanding (Weighted Average) averaged around $121.9 million, with its median value being $131.1 million (2024).
  • Per our database at Business Quant, Cytek Biosciences' Shares Outstanding (Weighted Average) surged by 7527.7% in 2022 and then crashed by 371.0% in 2024.
  • Cytek Biosciences' Shares Outstanding (Weighted Average) (Quarter) stood at $76.7 million in 2021, then skyrocketed by 75.28% to $134.5 million in 2022, then grew by 0.57% to $135.3 million in 2023, then decreased by 3.45% to $130.6 million in 2024, then fell by 2.3% to $127.6 million in 2025.
  • Its last three reported values are $127.6 million in Q3 2025, $127.6 million for Q2 2025, and $128.3 million during Q1 2025.